

On eve of CPHI Hanns-Christian Mahler stresses the importance of holistic sterile drug product development

Basel, October 23, 2023: On the eve of CPHI, ten23 health®, a global contract development and manufacturing organization, today announced that CEO Hanns-Christian Mahler will give a webinar stressing the importance of holistic sterile drug product development. While the number of parenteral drugs reaching market continues to rise Mahler is concerned that their multiple components are still being optimised in silos and wants to ensure the issue is front of mind for attendees at the world's largest pharma industry meeting.

"It is becoming increasingly apparent that all components and parameters of parentals can and do interact leading to issues in stability, usability and manufacturing," says Mahler, "As products become increasingly complex, I strongly believe that adopting a holistic approach towards drug development is the only way to ensure patients receive their full benefits. At ten23 health we see that doing so helps us to anticipate and mitigate issues, to ensure an efficient development & commercialization pathway. With this webinar and at CPHI we look forward to spreading this message amongst the global pharma community."

Webinar details:

Title: The Importance of Holistic Sterile Drug Product Development Online, Monday 23.10.23 5pm CET, registration here: <u>https://globalmeet.webcasts.com/viewer/event.jsp?ei=1634252&tp_key=09bb1dd8d5</u>

About ten23 health®

ten23 health®, located in Basel and Visp, Switzerland, is the human-centric and sustainable strategic partner of choice for the pharmaceutical industry and biotech start-ups: we develop, manufacture, and test modern medicines. At our two sites in Basel and Visp, Switzerland, we support our clients in developing, manufacturing and testing differentiated, stable, usable, and safe injectable treatment options for patients. ten23 health® combines the latest scientific findings with proven and tested world-class industry and regulatory expertise to forge new paths for supporting clients. We provide our innovative services in a fair and sustainable manner, respecting people's health and the future of our planet. ten23 health is solidly financed through the long-term commitment of 3i Group, an internationally reputable equity partner.

About BASE $\ensuremath{\mathbb{R}}$ and VIVA $\ensuremath{\mathbb{R}}$

BASE® and VIVA® are our two facilities in Basel and Visp Valais, Switzerland. It stands for our roots in Basel and life and nature in Valais. At ten23 health we embrace diversity with employees from different nationalities while still cherishing traditions. We are proud to be an employer in Switzerland where we can show our commitment to Patients, People and Planet.

About the company's name

The numeric value for the number of molecules in a sample of one mol is called Avogadro constant and equals 6.022 * 10 23. Gram quantities of material contain the incredible number of 10 23 atoms, which was an important discovery to understand the composition of matter: The world is built from small units, and not a homogeneous mass.

About 3i Group

3i is an investment company with two complementary businesses, Private Equity and Infrastructure, specializing in core investment markets in Northern Europe and North America. 3i's Private Equity team provides investment solutions for growing companies, backing entrepreneurs and management teams of mid-market companies with an Enterprise Value typically between €100m - €500m. The company backs international growth plans, providing access to its network and expertise to accelerate the growth of companies across the consumer, industrial, healthcare and business and technology services industries.

Media contacts:

ten23 health: Mara Willa, <u>mara.willa@ten23.health</u>; +4179 489 39 05
3i Group: Kathryn van der Kroft, <u>Kathryn.VanDerKroft@3i.com</u>; +44 20 7975 3021